Figure 1: Kaplan-Meier survival analysis of overall survival related to the expression of ANXA7 (71 patients). The patients whose tumors had high cytoplasmic ANXA7 expression (group 3) had significantly shorter survival than patients whose tumors had weak or moderate ANXA7 expression (group 1 and 2). The 5-year survival is 25% for group 3, 66% for group 2 and 100% for group 1.